BR0109477A - Uso de cdp-colina para o tratamento da sìndrome da supressão do álcool - Google Patents

Uso de cdp-colina para o tratamento da sìndrome da supressão do álcool

Info

Publication number
BR0109477A
BR0109477A BR0109477-7A BR0109477A BR0109477A BR 0109477 A BR0109477 A BR 0109477A BR 0109477 A BR0109477 A BR 0109477A BR 0109477 A BR0109477 A BR 0109477A
Authority
BR
Brazil
Prior art keywords
choline
cdp
treatment
alcohol
syndrome
Prior art date
Application number
BR0109477-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Rafael Foguet
Jorge Ramentol
Rafael Lozano
Julian Agut
Jesus Torres
Manuel M Raga
Josep M Castello
Jose A Ortiz
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of BR0109477A publication Critical patent/BR0109477A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
BR0109477-7A 2000-03-29 2001-03-28 Uso de cdp-colina para o tratamento da sìndrome da supressão do álcool BR0109477A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200000765A ES2170649B1 (es) 2000-03-29 2000-03-29 Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
PCT/EP2001/003536 WO2001072288A2 (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome

Publications (1)

Publication Number Publication Date
BR0109477A true BR0109477A (pt) 2003-06-03

Family

ID=8492914

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109477-7A BR0109477A (pt) 2000-03-29 2001-03-28 Uso de cdp-colina para o tratamento da sìndrome da supressão do álcool

Country Status (21)

Country Link
US (1) US6894032B2 (enExample)
EP (1) EP1267892B1 (enExample)
JP (1) JP4724348B2 (enExample)
KR (1) KR100794891B1 (enExample)
AT (1) ATE281172T1 (enExample)
AU (2) AU2001262141B2 (enExample)
BR (1) BR0109477A (enExample)
CA (1) CA2402707C (enExample)
CZ (1) CZ298933B6 (enExample)
DE (1) DE60106890T2 (enExample)
DK (1) DK1267892T3 (enExample)
ES (1) ES2170649B1 (enExample)
IL (2) IL151163A0 (enExample)
MX (1) MXPA02009442A (enExample)
NO (1) NO329766B1 (enExample)
NZ (1) NZ520825A (enExample)
PL (1) PL199291B1 (enExample)
PT (1) PT1267892E (enExample)
RU (1) RU2251422C2 (enExample)
WO (1) WO2001072288A2 (enExample)
ZA (1) ZA200206349B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
EP1541154A1 (en) * 2002-07-11 2005-06-15 Yamasa Corporation Medicinal composition for drug-induced neuropathy
CN100430066C (zh) 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
AU2003299715A1 (en) * 2002-12-20 2004-07-22 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
EP1765075A4 (en) 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
WO2006020703A1 (en) 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
RU2072239C1 (ru) * 1991-01-11 1997-01-27 Институт биохимии СО РАМН Способ коррекции метаболической зависимости от алкоголя и средство л.е.панина для его осуществления
DE4342173A1 (de) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
CA2193967C (en) * 1994-07-01 2007-09-11 Reid W. Von Borstel Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
KR100217488B1 (ko) * 1997-06-03 1999-09-01 맹섭 골프채의 헤드커버
RU2127589C1 (ru) * 1997-06-03 1999-03-20 Порембский Ярослав Олегович Способ лечения стрессорных поражений нервной системы
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Also Published As

Publication number Publication date
DK1267892T3 (da) 2005-03-07
EP1267892B1 (en) 2004-11-03
NO20024574L (no) 2002-11-22
ES2170649A1 (es) 2002-08-01
ATE281172T1 (de) 2004-11-15
WO2001072288A3 (en) 2002-05-10
EP1267892A2 (en) 2003-01-02
MXPA02009442A (es) 2003-02-12
PT1267892E (pt) 2005-03-31
US6894032B2 (en) 2005-05-17
CZ298933B6 (cs) 2008-03-12
NZ520825A (en) 2004-04-30
KR20030005248A (ko) 2003-01-17
PL199291B1 (pl) 2008-09-30
AU6214101A (en) 2001-10-08
KR100794891B1 (ko) 2008-01-14
DE60106890T2 (de) 2005-11-03
NO329766B1 (no) 2010-12-13
PL363177A1 (en) 2004-11-15
ZA200206349B (en) 2003-08-08
WO2001072288A2 (en) 2001-10-04
US20030162749A1 (en) 2003-08-28
CA2402707A1 (en) 2001-10-04
ES2170649B1 (es) 2003-06-16
NO20024574D0 (no) 2002-09-24
IL151163A0 (en) 2003-04-10
JP4724348B2 (ja) 2011-07-13
RU2002129579A (ru) 2004-03-27
RU2251422C2 (ru) 2005-05-10
DE60106890D1 (de) 2004-12-09
AU2001262141B2 (en) 2005-03-10
CZ20023245A3 (cs) 2003-03-12
IL151163A (en) 2011-01-31
JP2003528133A (ja) 2003-09-24
CA2402707C (en) 2007-11-13

Similar Documents

Publication Publication Date Title
BR0213358A (pt) Uso de flibanserina
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
BR0015188A (pt) Composições farmacêuticas
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0111266A (pt) Sìntese reduzida de derivados de 3,3-diarilpropilamina
SE0102440D0 (sv) New compound
GEP20053617B (en) Bridged Piperazine Derivatives
BR0109477A (pt) Uso de cdp-colina para o tratamento da sìndrome da supressão do álcool
PT1150704E (pt) Melagatran para o tratamento da inflamacao
ES2136581B1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
AP1530A (en) Pharmaceutical composition for intramuscular injection containing loxoprofen.
BR0107160A (pt) Uso de um éter cìclico para o preparo de medicamentos que afetam a tolerância à glicose
BR0008519A (pt) Aplicação de sistemas tiazol policìclicos para apreparação de medicamentos para a profilaxia outratamento da obesidade
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2179526T3 (es) Analogos y profarmacos del paclitaxel solubles en agua.
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.
AU2002220654A1 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
BR0316441A (pt) Utilização de um composto, composto e medicamento

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/00

Ipc: A61K 31/70 (2011.01), A61P 25/32 (2011.01)

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.